Orano Med
Julien B. has extensive experience in the engineering and maintenance fields, currently serving as the Responsable service technique at Orano Med since May 2012. Julien leads a multidisciplinary team focused on the operation and development of various installations, including LMT, CRD, ARCoLab, and ATEF. Previously, Julien held the position of Ingénieur projets et responsable Maintenance, managing industrial development projects related to processes and maintenance services. Prior to Orano Med, Julien worked in environmental monitoring at Areva and served in several roles, including Technicien d'exploitation and Assistant Ingénieur Traitement des effluents industriels. Julien holds a Master 2 in Génie industriel from Université Paris-Est Créteil, and multiple degrees in Chemistry and Industrial Engineering from Université de Limoges and IUT de Limoges.
This person is not in any offices
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.